3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
69
Lymphoma
20
Lymphoma, Mantle-Cell
19
Leukemia, Myeloid, Acute
17
Leukemia, Lymphocytic, Chronic, B-Cell
17
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Lymphoma, Non-Hodgkin
15
Neoplasms, Plasma Cell
14
Lymphoma, Large B-Cell, Diffuse
14
Lymphoma, Follicular
13
Lymphoma, B-Cell, Marginal Zone
12
Unspecified Adult Solid Tumor, Protocol Specific
10
Hodgkin Disease
10
Lymphoma, Large-Cell, Anaplastic
9
Immunoblastic Lymphadenopathy
9
Waldenstrom Macroglobulinemia
8
Recurrence
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia
8
Burkitt Lymphoma
8
Myelodysplastic Syndromes
7
Lymphoma, T-Cell, Cutaneous
7
Head and Neck Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Sezary Syndrome
6
Neoplasms
6
Mycosis Fungoides
6
Lymphoma, Large-Cell, Immunoblastic
6
Congenital Abnormalities
6
Breast Neoplasms
6
Interventions
Methylprednisolone
2
Filgrastim
2
Cyclophosphamide
2
siltuximab
1
sargramostim
1
pyroxamide
1
ibrutinib
1
Topotecan
1
Tetradecanoylphorbol Acetate
1
Tacrolimus
1
Standard of Care
1
Prednisone
1
Practice Guidelines as Topic
1
Peripheral Blood Stem Cell Transplantation
1
Leucovorin
1
Interleukin-12 Subunit p35
1
Interferon-alpha
1
Imatinib Mesylate
1
Fluorouracil
1
Etoposide
1
Decitabine
1
Cyclosporine
1
Cladribine
1
Cilengitide
1
Carboplatin
1
Bortezomib
1
Antilymphocyte Serum
1
Amifostine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Monoclonal Gammopathy of Undetermined Significance
×
Bortezomib
×
Clear all
NCT00006362
2011-08-03
PS-341 in Treating Patients With Advanced Cancer
Mayo Clinic
Phase 1
Completed